Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas

Science Translational Medicine

Volumn 4, Issue 116, 2012, Pages

  Elkhaled, Adam ^a   Jalbert, Llewellyn E ^b   Phillips, Joanna J ^a   Yoshihara, Hikari A I ^a   Parvataneni, Rupa ^a   Srinivasan, Radhika ^a   Bourne, Gabriela ^a   Berger, Mitchel S ^a   Chang, Susan M ^a   Cha, Soonmee ^a   Nelson, Sarah J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; ANTINEOPLASTIC AGENT; CHOLINE; GENOMIC DNA; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; UNCLASSIFIED DRUG; ALPHA-HYDROXYGLUTARATE; GLUTARIC ACID DERIVATIVE; IDH1 PROTEIN, HUMAN;

ARTICLE; ASTROCYTOMA; BRAIN TISSUE; CANCER GRADING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFUSION; EX VIVO STUDY; GENE; GENE MUTATION; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; ISOCITRATE DEHYDROGENASE 1 GENE; MAJOR CLINICAL STUDY; MITOSIS RATE; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIOMA; PATIENT SELECTION; PRIORITY JOURNAL; PROTON HIGH RESOLUTION MAGIC ANGLE SPINNING MAGNETIC RESONANCE SPECTROSCOPY; RECURRENT CANCER; TREATMENT RESPONSE; AMINO ACID SEQUENCE; BRAIN TUMOR; CHEMISTRY; ENZYMOLOGY; GENETICS; IMAGE QUALITY; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; WORLD HEALTH ORGANIZATION;

AMINO ACID SEQUENCE; BASE SEQUENCE; BRAIN NEOPLASMS; DNA MUTATIONAL ANALYSIS; GLIOMA; GLUTARATES; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM GRADING; PHANTOMS, IMAGING; WORLD HEALTH ORGANIZATION;

EID: 84862907969     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002796     Document Type: Article

References (33)

1. J. T. Grier, T. Batchelor, Low-grade gliomas in adults. Oncologist 11, 681-693 (2006).
2. M. J. Riemenschneider, G. Reifenberger, Molecular neuropathology of low-grade gliomas and its clinical impact. Adv. Tech. Stand. Neurosurg. 35, 35-64 (2010).
3. H. Yan, D. W. Parsons, G. Jin, R. McLendon, B. A. Rasheed, W. Yuan, I. Kos, I. Batinic-Haberle, S. Jones, G. J. Riggins, H. Friedman, A. Friedman, D. Reardon, J. Herndon, K. W. Kinzler, V. E. Velculescu, B. Vogelstein, D. D. Bigner, IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773 (2009).
4. D. W. Parsons, S. Jones, X. Zhang, J. C. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, I. M. Siu, G. L. Gallia, A. Olivi, R. McLendon, B. A. Rasheed, S. Keir, T. Nikolskaya, Y. Nikolsky, D. A. Busam, H. Tekleab, L. A. Diaz Jr., J. Hartigan, D. R. Smith, R. L. Strausberg, S. K. Marie, S. M. Shinjo, H. Yan, G. J. Riggins, D. D. Bigner, R. Karchin, N. Papadopoulos, G. Parmigiani, B. Vogelstein, V. E. Velculescu, K. W. Kinzler, An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008).
5. C. Houillier, X. Wang, G. Kaloshi, K. Mokhtari, R. Guillevin, J. Laffaire, S. Paris, B. Boisselier, A. Idbaih, F. Laigle-Donadey, K. Hoang-Xuan, M. Sanson, J. Y. Delattre, IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75, 1560-1566 (2010).
6. C. Hartmann, B. Hentschel, W. Wick, D. Capper, J. Felsberg, M. Simon, M. Westphal, G. Schackert, R. Meyermann, T. Pietsch, G. Reifenberger, M. Weller, M. Loeffler, A. von Deimling, Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: Implications for classification of gliomas. Acta Neuropathol. 120, 707-718 (2010).
7. +-dependent isocitrate dehydrogenase plays a key role in lipid metabolism. J. Biol. Chem. 279, 39968-39974 (2004).
8. +-dependent isocitrate dehydrogenase. J. Biol. Chem. 276, 16168-16176 (2001).
9. +-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic. Biol. Med. 32, 1185-1196 (2002).
10. L. Dang, D. W. White, S. Gross, B. D. Bennett, M. A. Bittinger, E. M. Driggers, V. R. Fantin, H. G. Jang, S. Jin, M. C. Keenen, K. M. Marks, R. M. Prins, P. S. Ward, K. E. Yen, L. M. Liau, J. D. Rabinowitz, L. C. Cantley, C. B. Thompson, M. G. Vander Heiden, S. M. Su, Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739-744 (2009).
11. D. Capper, H. Zentgraf, J. Balss, C. Hartmann, A. von Deimling, Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 118, 599-601 (2009).
12. S. Meiboom, D. Gill, Modified spin-echo method for measuring nuclear relaxation times. Rev. Sci. Instrum. 29, 688-691 (1958).
13. M. G. Swanson, K. R. Keshari, Z. L. Tabatabai, J. P. Simko, K. Shinohara, P. R. Carroll, A. S. Zektzer, J. Kurhanewicz, Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magn. Reson. Med. 60, 33-40 (2008).
14. V. Govindaraju, K. Young, A. A. Maudsley, Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 13, 129-153 (2000).
15. R. Srinivasan, J. J. Phillips, S. R. Vandenberg, M. Y. Polley, G. Bourne, A. Au, A. Pirzkall, S. Cha, S. M. Chang, S. J. Nelson, Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. Neuro Oncol. 12, 1152-1161 (2010).
16. S. J. Nelson, Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI. NMR Biomed. 24, 734-749 (2011).
17. S. Zhao, Y. Lin, W. Xu, W. Jiang, Z. Zha, P. Wang, W. Yu, Z. Li, L. Gong, Y. Peng, J. Ding, Q. Lei, K. L. Guan, Y. Xiong, Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1a. Science 324, 261-265 (2009).
18. R. Chowdhury, K. K. Yeoh, Y. M. Tian, L. Hillringhaus, E. A. Bagg, N. R. Rose, I. K. H. Leung, X. S. Li, E. C. Y. Woon, M. Yang, M. A. McDonough, O. N. King, I. J. Clifton, R. J. Klose, T. D. W. Claridge, P. J. Ratcliffe, C. J. Schofield, A. Kawamura, The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 12, 463-469 (2011).
19. C. Choi, G. Sandeep, R. DeBerardinis, Z. Kovacs, R. Bachoo, J. Pascual, I. Dimitrov, B. Mickey, C. Malloy, E. Maher, In vivo detection of IDH mutations in gliomas by 1H-MRS. Proc. Intl. Soc. Mag. Reson. Med. 19, 181 (2011).
20. R. Nagarajan, M. A. Thomas, W. B. Pope, R. M. Prins, N. Wilson, N. Salamon, L. M. Liau, Detection of 2-hydroxyglutarate in mutant brain tumors in vivo using proton magnetic resonance spectroscopy. Proc. Intl. Soc. Mag. Reson. Med. 19, 184 (2011).
21. O. C. Andronesi, G. Kim, E. Gerstner, T. Batchelor, A. A. Tzika, V. R. Fantin, M. G. Vander Heiden, A. G. Sorensen, Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci. Transl. Med. 4, 116ra4 (2012).
22. P. Paschka, R. F. Schlenk, V. I. Gaidzik, M. Habdank, J. Krönke, L. Bullinger, D. Späth, S. Kayser, M. Zucknick, K. Götze, H. A. Horst, U. Germing, H. Döhner, K. Döhner, IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J. Clin. Oncol. 28, 3636-3643 (2010).
23. M. Aghili, F. Zahedi, E. Rafiee, Hydroxyglutaric aciduria and malignant brain tumor: A case report and literature review. J. Neurooncol. 91, 233-236 (2009).
24. K. E. Yen, M. A. Bittinger, S. M. Su, V. R. Fantin, Cancer-associated IDH mutations: Biomarker and therapeutic opportunities. Oncogene 29, 6409-6417 (2010).
25. Z. J. Reitman, H. Yan, Isocitrate dehydrogenase 1 and 2 mutations in cancer: Alterations at a crossroads of cellular metabolism. J. Natl. Cancer Inst. 102, 932-941 (2010).
26. I. Park, A. P. Chen, M. L. Zierhut, E. Ozturk-Isik, D. B. Vigneron, S. J. Nelson, Implementation of 3 T lactate-edited 3D 1H MR spectroscopic imaging with flyback echo-planar readout for gliomas patients. Ann. Biomed. Eng. 39, 193-204 (2011).
27. P. J. Basser, C. Pierpaoli, Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J. Magn. Reson. B 111, 209-219 (1996).
28. T. R. McKnight, S. M. Noworolski, D. B. Vigneron, S. J. Nelson, An automated technique for the quantitative assessment of 3D-MRSI data from patients with glioma. J. Magn. Reson. Imaging 13, 167-177 (2001).
29. 1H HR-MAS spectroscopy of prostate tissue. Magn. Reson. Med. 61, 525-532 (2009).
30. D. Stefan, F. Di Cesare, A. Andrasescu, E. Popa, A. Lazariev, E. Vescovo, O. Strbak, S. Williams, Z. Starcuk, M. Cabanas, D. van Ormondt, D. Graveron-Demily, Quantitation of magnetic resonance spectroscopy signals: The jMRUI software package. Meas. Sci. Technol. 20, 104035 (2009).
31. H. Ratiney, M. J. Albers, H. Rabeson, J. Kurhanewicz, Semi-parametric time-domain quantification of HR-MAS data from prostate tissue. NMR Biomed. 23, 1146-1157 (2010).
32. Z. Feng, D. McLerran, J. Grizzle, A comparison of statistical methods for clustered data analysis with Gaussian error. Stat. Med. 15, 1793-1806 (1996).
33. F. E. Harrell Jr., Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression and Survival Analysis (Springer, New York, 2001).